Comments to FDA: Developing Nicotine Replacement Therapy Drug Products Share page: Docket Number: FDA-2019-D-0297 CHPA welcomes the opportunity to comment on the draft guidance on indications for nicotine replacement therapies (NRT). Download Document Issues: OTC Medicines Rx-to-OTC Switch Other Issues Research Related Posts Articles Polibrief: Consumer Data Privacy: State Efforts to Preserve Privacy Apr 16, 2024 Press Releases and Statements Self-Care Industry Representatives Participate in Capitol Hill Briefing Highlighting Legislative Priorities Apr 11, 2024 Press Releases and Statements Kentucky Expands Access to OTC Cold & Allergy Medications Containing PSE Apr 8, 2024